TWiPO #7 ~ Interview with E. Anders Kolb and Andrew Napper on drug development

June
02, 2011
In this seventh episode of "This Week in
Pediatric Oncology" TWiPO podcast, host Dr. Tim Cripe interviews Dr. E.
Anders Kolb and Dr. Andrew Napper  from
Nemours in Wilmington, Delaware.
This informative discussion covers the
strategies, scope, and challenges of target discovery, drug development, and
preclinical testing for pediatric cancers, a complex process that has been
accelerated by high throughput screening technology that has only recently
become available in academic settings.
Dr. Kolb is the Director of Blood and Bone
Marrow Transplantation at Alfred I. duPont Hospital for Children, and Head of
the Cancer Therapeutics Laboratory at Nemours Biomedical Research. He is also a
Principal Investigator in the Pediatric Preclinical Testing
Program (PPTP), a comprehensive program to
systematically evaluate new agents against childhood solid tumor and leukemia
models.
Dr. Andrew Napper joined the research team at
the Nemours Center for Childhood Cancer Research (NCCCR) in 2009 to establish
its High Throughput Screening and Drug Discovery Laboratory. Dr. Napper came to
Nemours from the University of Pennsylvania, where he was the Director of High
Throughput Screening for the Penn Center for Molecular Discovery, one of the
original ten centers established as part of the National Institutes of Health’s
Roadmap initiative to discover drugs for neglected diseases.
For more information on this program and
technology:
Lab Offer Hope for Kids with Cancer, Wilmington News Journal
(8/24/09)
Academic screening goes high-throughput, Nature Methods 7, 787–792
(2010)
Please send questions and comments to
twipo@solvingkidscancer.org